Paul Wallace
Direttore/Membro del Consiglio presso Stroma Biosciences Ltd.
Posizioni attive di Paul Wallace
Società | Posizione | Inizio | Fine |
---|---|---|---|
Stroma Biosciences Ltd.
Stroma Biosciences Ltd. Miscellaneous Commercial ServicesCommercial Services Stroma Biosciences Ltd. is a biopharmaceutical company based in Cambridge, UK. Stroma Biosciences is focused on developing novel anti-stromal therapies to treat cancer by targeting survival signals in the tumour stroma, thereby cutting this important lifeline for cancer cells. The British company's work is focused on mesenchymal stroma cells, which are essential for tumour growth and resistance to cancer therapies. Stroma Biosciences has developed a platform to develop novel first-in-class cancer therapeutics by targeting the stromal compartment. The company has a validated disease-activated platform screening primary tumour samples, and its emerging pipeline includes several stromal targets to treat both solid and haematological malignancies. The company was founded in 2020 by Ingo Ringshausen, Andrew Douglas Moore, and Clive Stanway. | Direttore/Membro del Consiglio | 01/01/2021 | - |
Storia della carriera di Paul Wallace
Precedenti posizioni note di Paul Wallace
Società | Posizione | Inizio | Fine |
---|---|---|---|
MEDIVIR AB | Corporate Officer/Principal | 01/01/2000 | 28/02/2015 |
Formazione di Paul Wallace
University of Cambridge | Doctorate Degree |
Statistiche
Distribuzione geografica
Regno Unito | 3 |
Svezia | 2 |
Posizioni
Corporate Officer/Principal | 1 |
Doctorate Degree | 1 |
Director/Board Member | 1 |
Settori
Health Technology | 2 |
Consumer Services | 2 |
Commercial Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
MEDIVIR AB | Health Technology |
Aziende private | 1 |
---|---|
Stroma Biosciences Ltd.
Stroma Biosciences Ltd. Miscellaneous Commercial ServicesCommercial Services Stroma Biosciences Ltd. is a biopharmaceutical company based in Cambridge, UK. Stroma Biosciences is focused on developing novel anti-stromal therapies to treat cancer by targeting survival signals in the tumour stroma, thereby cutting this important lifeline for cancer cells. The British company's work is focused on mesenchymal stroma cells, which are essential for tumour growth and resistance to cancer therapies. Stroma Biosciences has developed a platform to develop novel first-in-class cancer therapeutics by targeting the stromal compartment. The company has a validated disease-activated platform screening primary tumour samples, and its emerging pipeline includes several stromal targets to treat both solid and haematological malignancies. The company was founded in 2020 by Ingo Ringshausen, Andrew Douglas Moore, and Clive Stanway. | Commercial Services |
- Borsa valori
- Insiders
- Paul Wallace
- Esperienza